GENE ONLINE|News &
Opinion
Blog

2021-07-04| M&ASpecial

EQT Private Equity and Goldman Sachs Spend $8.5 Billion to Acquire Parexel

by Daniel Ojeda
Share To
On July 2nd, EQT Private Equity, a Swedish firm part of EQT AB, announced it would team up with Goldman Sachs to acquire Parexel, a clinical research organization (CRO). They would buy it from its current owner Pamplona Capital Management for $8.5 billion. The announcement comes amid EQT Private Equity’s restructuring of its healthcare-related holdings.  

GO Prime with only $1.49 now

LATEST
Absci Accelerates Breakthroughs in AI-Designed Drugs with AstraZeneca and Almirall Collaborations
2023-12-06
Saving Lives Through Communication, Heroic Faith Medical Science Showcasing Novel AI Auscultation Tool for Procedural Sedation Patients in PGA 77
2023-12-05
AbbVie Invests $10.1 Billion in ImmunoGen, Targeting the Ovarian Cancer Landscape
2023-12-05
PRISM BioLab and Eli Lilly Join Forces in Revolutionary Drug Discovery Collaboration
2023-12-05
Novel Hydrogel Delivery System Could Reduce Daily Diabetes Injections to Three Times a Year
2023-12-04
Unveiling the Role of Microbes in Climate Change at COP28
2023-12-04
GeneOnline’s Weekly News Highlights: Nov 20-Nov 24
2023-11-27
EVENT
Scroll to Top